RESEARCH TRIANGLE PARK, N.C., December 18, 2025--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug ...
Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...
In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
Detailed price information for Simulations Plus Inc (SLP-Q) from The Globe and Mail including charting and trades.
The Congressional Budget Office (CBO) informs Congress about the costs or revenue changes associated with proposed legislation, a challenging enough task on its own. Sometimes, the CBO is asked to ...
Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback